Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma
Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma
Momentum Public Relations
Press Release: May 17, 2017
OTTAWA, ONTARIO–(Marketwired – May 23, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.
Per the definitive agreement, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future cannabinoid-based products.
Tetra will work in close collaboration with Panag’s team of experts to ensure a rapid and successful development leading to marketing authorization. Panag will continue work in the development of novel products for unmet medical need and Tetra will take the lead in commercializing these novel drug products.
“We are very pleased to announce this partnership with Panag as we work towards building an innovative product pipeline focused on cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Tetra is committed to generating revenues in 2017 by launching several products in the retail market through its partnership with Panag.”
Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the local treatment of pain and inflammation. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.
“We will prioritize the development of the ocular therapy as this is a promising innovative product with high medical need and a significant potential financial reward,” said Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma. Tetra has positioned itself to become a leader in topical pain relief.
Corporate Update:
Tetra changed today at the opening of the U.S. markets its OTCQB stock symbol to TBPMF.
The Company issued 501,800 new shares as part as of a service agreement as previously announced in a news release on June 20, 2016.
The Company issued an additional 250,000 new shares as part of a service agreement with MAPH Enterprises, LLC, effective May 8, 2017 to broaden U.S. investor awareness.
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in the area of pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
About Tetra Bio-Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Source: Tetra Bio-Pharma Inc.
CONTACT INFORMATION
-
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
DIAGNOS Acquires Interest in Majescor Resources Inc.
DIAGNOS Acquires Interest in Majescor Resources Inc.
Momentum Public Relations
Press Release: May 17, 2017
BROSSARD, QUEBEC–(Marketwired – May 17, 2017) – Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX VENTURE:ADK), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces that, as stated in a news release dated May 17th, 2017 by Majescor Resources Inc. (“Majescor” or the “Issuer”), Majescor has received regulatory and shareholders’ approval for the issuance to the Corporation of 8,000,000 common shares (“Shares”) pursuant to the sale of the assets from its mining division announced on March 15th, 2017. The news release from Majescor triggered the requirement to file an early warning report (“Form 62-103F1”) by DIAGNOS and to publish this press release.
DIAGNOS currently owns 2,500,000 Shares of the Issuer representing an approximate 6.18{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the outstanding Shares of the Issuer on an undiluted basis and partially diluted basis. Immediately following the issuance of 8,000,000 Shares, DIAGNOS will own, directly and indirectly, 10,500,000 Shares, representing an approximate 21.68{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} interest in the Issuer on an undiluted basis and partially diluted basis.
DIAGNOS’ investment in Shares of Majescor is solely for investment purposes. Based upon subsequent developments affecting the Issuer or its business and the general market and economic conditions, DIAGNOS may decide to purchase additional securities of the Issuer or may decide to sell all or part of its investments.
A copy of Form 62-103F1 can be found on SEDAR.com or may be obtained by submitting a written request to:
Diagnos Inc. |
c/o Accounting and Legal Dept. |
7005 Taschereau Blvd, suite 340 |
Brossard, Qc, J4Z 1A7 |
450-678-8882 ext. 235 |
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and in Mexico.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
DIAGNOS Inc.
Marc-Andre Massue
CFO
1-877-678-8882 or (450) 678-8882, ext.: 235
- Published in Albert Mining, Mining, News Home
Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease
Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease
Momentum Public Relations
Press Release: May 17, 2017
OTTAWA, ONTARIO–(Marketwired – May 17, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.
The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.
“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”
Background Information:
Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.
Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.
About Tetra-Bio Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Majescor Resources Receives the Approval From the TSX-V for the Acquisition of the Mining Division Of Diagnos
Majescor Resources Receives the Approval From the TSX-V for the Acquisition of the Mining Division Of Diagnos
Momentum Public Relations
Press Release: May 17, 2017
Ottawa, Ontario / TheNewswire / May17, 2017 – Majescor Resources Inc. (“Majescor” or the “Company”) (TSX-V: MJX) is pleased to announce that it has received TSX-V Exchange approval for the acquisition of the mining division of Diagnos Inc. (“DIAGNOS”) (reference: News release of March 15, 2017). The Company has also received written consents of the majority of its disinterested shareholders for the creation of a new Control Person, DIAGNOS.
“We are pleased to move forward with this strategic acquisition. This is a game changer for Majescor. It puts us in the forefront in becoming the leader in using artificial intelligence and machine learning for mineral exploration. DIAGNOS has over a 10-year track record of using and perfecting its CARDS (Computer Aided Resources Detection System) and we are excited about the added value that Majescor will now be able to provide to our own mineral projects as well as the potential for revenue-generating third party applications”, stated Andre Audet, President and CEO of Majescor.
Under the terms of the agreement, Majescor will issue 8,000,000 common shares of its share capital to DIAGNOS, at a deemed price of $0.10 per share, in payment for the acquisition of the assets, consisting of DIAGNOS’ mining claims, royalty agreements, and the CARDS system. Additionally, Majescor will remit to DIAGNOS (i) 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of any payment that Majescor receives from the royalty agreements forming part of the acquired assets, and (ii) 5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of revenues generated by the commercialization of the CARDS system.
The common shares issued to DIAGNOS will bear a restrictive legend for four months and one day. As a result of the issuance of the 8,000,000 common shares to DIAGNOS, Majescor has 48,427,775 common shares issued and outstanding.
About Majescor Resources Inc.
Majescor is a junior mining exploration company with an extensive portfolio of gold and diamond properties in Quebec.
For further information, please contact:
Andre Audet
President & CEO of Majescor Resources Inc.
Telephone: 613-241-5333
Fax: 613-422-0773
Email: andre@evertonresources.com
Website: www.majescor.com
Additional information about the Corporation is available under Majescor’s profile on SEDAR at www.sedar.com.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or are events or conditions that “will”, “would”, “may”, “could” or “should” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: the resumption of the trading of Majescor shares on the TSX Venture Exchange. Statements regarding future production, capital expenditures and development plans are subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and gas that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These risks include, but are not limited to, inflation or lack of availability of goods and services, environmental risks, drilling risks, regulatory changes and certain other known and unknown risks detailed from time to time in Majescor’s public disclosure documents, copies of which are available on Majescor’s SEDAR profile at www.sedar.com.
Although Majescor believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Majescor’s actual results may differ materially from those expressed or implied in forward-looking statements and readers should not place undue importance or reliance on the forward-looking statements. Statements including forward-looking statements are made as of the date they are given and except as required by applicable securities laws, Majescor disclaims any intention or obligation to publically update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2017 TheNewswire – All rights reserved.
- Published in Albert Mining, Mining, News Home
The Cost of Climate Change
The Cost of Climate Change
Annual costs for natural disasters in Canada pegged at almost $5 billion
Canada has just experienced extensive flooding in British Columbia, Ontario and Quebec. The complete cost of the disasters won’t be added up for some time; but you can bet that this past spring is going to be one of the most expensive on record. In Canada and throughout the world, we are being battered by increasingly numerous weather events, both extreme and not-so-extreme. The climate is changing.
Trying to get a handle on just exactly how much we are paying for climate change is difficult. The Office of the Parliamentary Budget Officer has tried. In its Estimate of the Average Annual Cost for Disaster Financial Assistance Arrangements due to Weather Events, released on February 25, 2016, it comes to $4.92 billion. This is the total annual cost from hurricanes convective storms, winter storms and flooding. But this, of course, does not take into account the lost productivity resulting from weather events.
The May 9, 2017 edition of Canadian Underwriter noted that in the United States, the bill for severe flooding in April would reach the multi-billion dollar range. Severe weather in America continued to be the largest factor in global insurance losses for 2017. While extreme weather or – as they like to say, weather events – continue to get worse, we in North America have comparatively little to worry about. Consider the plight of those low-lying Pacific Ocean nations that face the prospect of disappearing; if the ice in the Arctic and Antarctic continues to melt, and the oceans continue to rise.
It has been demonstrably and scientifically proven that climate change – the gradual warming of the earth’s surface – is to a very large degree driven by the fossil fuels used to heat our homes and drive our industry and vehicles. The very sad fact behind the spectre of increasing temperatures and increased hurricanes, is that we have the technology to prevent further damage.
One rewarding characteristic of humans is that we seldom throw in the towel, and so ideas that may have seemed farfetched or even ridiculous a generation ago, sometimes have their place in the sun. The green roofs of Toronto are a good example of this. In May 2009 Toronto City Council passed a bylaw that requires that new residential, office and industrial buildings have a green roof. While the idea of building roof-top gardens is as old as the hills (think of the hanging gardens of Babylon), doing so for ecological reasons is a relatively new concept.
The simple fact is that by going green you make money by saving money.
The Toronto bylaw applies to buildings that contain 6,000 square meters of floor space or more. The percentage of the roof to be green ranges from 20{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for buildings with a floor space of 6,000 square meters, to 60{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for buildings with over 20,000 square meters of floor space. Residential buildings shorter than six storeys or 20 meters in height are exempt. Toronto based its green roof policy on studies conducted by professors at Ryerson University, that showed potential annual cost savings of $37.1 million dollars. The largest cost-saving category was commercial building energy. The category showed a potential cost reduction of $21.56 million annually. The comfort benefit is hard to calculate, because how do you quantify mitigating the heat sink caused by our predilection for creating concrete canyons? As you might imagine, green roofs have also been cited as a partial solution for some of the flooding that has recently occurred. This is because of the green roofs’ ability to absorb rain and reduce water runoff. Oddly enough, building green roofs can also prolong their lifespan.
If we are to avoid the rapidly approaching climate Armageddon, it is vital that climate change deniers and vapid naysayers learn the real truth about green energy and efficiency. Simply put, energy efficiency is going to be one of the leading industries of the future because it makes you money by saving you money. As the Toronto study shows, green roofs save you money by reducing heating and cooling costs. Tesla, the electric car company, is now worth more than Ford. In an April 3, 2017 story CNN Money stated that Tesla was worth US$48 billion while Ford was valued at $45 billion.
Another energy-efficient way to go about saving the environment while saving money can be found in the ingenious technology of Burnaby-based International Wastewater Systems (“IWS”). IWS has developed a way to recover the heat usually lost in wastewater. Hot water from showers, baths, dishwashers and laundry goes down the drain. But IWS builds, installs and monitors closed systems that are used to heat the hot water supply in buildings. On May 10, 2017 the company announced that it had won funding and a contract to install five systems in Scotland through its wholly owned UK subsidiary SHARC Energy Systems. The contract is worth 9.8 million pounds. The five sites are the first of 750 locations targeted for conversion in Scotland.
In some ways the system is as simple as your own furnace. In the typical household furnace, natural gas or fuel oil is used to power a heat exchanger. The heat exchanger, in turn, warms the water in a radiator system, or the air in a forced air system. The genius in the IWS system was to develop a filtering system fine enough to prevent waste from clogging the heat exchanger. The system is completely sealed to ensure that there is no risk of water contamination, and continuously monitored to prevent any problems.
The return on investment (“ROI”) varies. A hospital in Boston, for example, that used electric boilers to heat its water had an IWS system installed. It cost $800,000, but the new system will save the hospital approximately $2 million per year and pay for itself within six months. IWS heat recovery systems can be installed in institutional, multi-residential, and industrial buildings. As described in a September 2016 interview with James West of the Midas Letter in the Financial Post, the payback period for residential buildings with 200 or so units is usually two to three years. If you are now telling yourselves this seems too good to be true, the real kicker is that the recovery systems have an anticipated lifespan of 40 years.
By Noel Meyer
- Published in Blog, Energy, Green Technology, International Wastewater Systems, Technology
Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients
Momentum PR ‘s client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the symbol GRPOF
Momentum PR is pleased to have produced an informative and comprehensive report on Tetra Bio-Pharma available on the Momentum PR LinkedIn page.
Tetra Bio-Pharma Highlights:
- – Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals- Global medical marijuana market is estimated to reach US$55.8 billion by 2025- Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products- Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
– Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
– Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017
Tetra Bio-Pharma is a Canadian-based pioneer, innovator and first market mover in developing cannabis-based pharmaceuticals. These are used for the treatment of cancer-related pain and the resultant nausea, as well as anorexia and Post Traumatic Stress Disorder (PTSD).
The global medical marijuana market is estimated to reach US$55.8 billion by 2025, according to Grand View Research. Health Canada has stated that they expected a mature medical marijuana market worth C$1.3 billion by 2024 in Canada alone.
Tetra Bio-Pharma is the first and only bio-pharmaceutical company in North-America that is focused on cannabinoid (CBD) clinical stage pain relief products. The Company believes that if all goes well, its flagship drug, PPP001, designed to treat the chronic pain associated with many cancers, will be on the market in 2019. The Canadian Cancer Society is estimating a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} growth rate in cancer cases in Quebec, and 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} nationally by 2030. They also advocate for more spending on research on innovative drugs and end-of-life treatment.
Tetra Bio-Pharma is accelerating the acceptance of cannabis-based medical treatments. It is the only bio-pharmaceutical company currently running a double-blind Phase 1 study. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single and multi-daily ascending doses of cannabis by smoking in healthy volunteers.
Pending a positive outcome, cannabis-based drugs designed to treat cancer pain and nausea from chemotherapy, PTSD and a number of other ailments will qualify for North-American Drug Identification Numbers (DIN). This means that prescriptions would be eligible for insurance coverage.
In addition to developing proprietary products and intellectual property, Tetra Bio-Pharma signed a supply agreement with ACMPR licensed producer Aphria Inc. on November 3, 2016. The Tetra-Aphria partnership was further solidified on April 19, 2017 when plans were announced for the joint distribution of dried medical cannabis for Quebec and the Atlantic Provinces.
The Momentum PR informative and comprehensive report on Tetra Bio-Pharma is available on the Momentum PR LinkedIn page.
If you would like more information on Tetra Bio-Pharma listed on the Canadian Securities Exchange under the symbol TBP with a market cap of C$ 70 million, or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid cap Canadian listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of TheNewswire.ca Inc., its partner newswires and / or associated news services.
– See more at: The Newswire
- Published in Blog, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Anfield Resources hires Venture Liquidity as market maker
Anfield Resources hires Venture Liquidity as market maker
Subject to regulatory approval, Anfield Resources Inc. has retained Venture Liquidity Partners Inc. to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the company. Venture Liquidity Partners is a specialized consulting firm based in Toronto providing a variety of services focused on TSX Venture Exchange-listed issuers.
The market-making service will be undertaken through a registered broker, W.D. Latimer Co. Ltd., in compliance with the applicable policies of the TSX-V and other applicable laws. For its services, the company has agreed to pay Venture Liquidity Partners $5,000 per month for a period of 12 months. The agreement may be terminated at any time by either Anfield or Venture Liquidity Partners. Anfield and Venture Liquidity Partners act at arm’s length, and Venture Liquidity Partners has no present interest, directly or indirectly, in the company or its securities. The finances and shares required for the market-making services are provided by W.D. Latimer. The fee paid by Anfield to Venture Liquidity Partners is for services only.
About Anfield Resources Inc.
Anfield is an energy metals exploration, development and near-term production company that is focused on two production centres:
- Arizona/Colorado/Utah — Shootaring Canyon mill: A key asset in Anfield’s existing conventional uranium portfolio is the Shootaring Canyon mill in Garfield county, Utah.
- Wyoming — Irigaray ISR (in situ recovery) processing plant (resin processing agreement): Anfield has also signed a resin processing agreement with Uranium One wherein Anfield would process up to 500,000 pounds per year of its mined material at Uranium One’s Irigaray processing plant in Wyoming.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Anfield Resources, Mining, News Home
Puma Exploration to begin Summer Exploration Program at Murray Brook Project
Puma Exploration to begin Summer Exploration Program at Murray Brook Project
RIMOUSKI, QUEBEC–(Marketwired – May 10, 2017) – Puma Exploration Inc. (TSX VENTURE:PUM)(SSE:PUMA) (the “Company” or “Puma”) is to begin its initial Exploration Program on the Murray Brook Project located in the famous Bathurst mining camp of northern New Brunswick, Canada. Puma has received all necessary permits to proceed with the projected work program which includes a first phase reconnaissance operation followed by trenching, stripping and drilling operations.
The Murray Brook Project consists of three (3) distinct contiguous areas that cover more than 18 kilometers of the favorable rock hosting the operating Caribou Mine (Trevali Mining Corporation), the Murray Brook Deposit and the past operating Restigouche Mine. From east to west, they are the Murray Brook East Property (4925), The Murray Brook Mining Lease (# 252) and the newly acquired Murray Brook West Property (7846). These areas have been subject to various degrees of exploration work but share the same potential to increase the mineral resources defined at the Murray Brook Deposit.
Murray Brook East (4925)
The Murray Brook East Property (4925) consists of 245 claims (5326 Hectares). Its eastern boundary is contiguous to the Caribou Mining Lease (# 246) and is located only four kilometres west of the producing Caribou mine owned and operated by Trevali Mining Corp. The previous operators of the Murray Brook Property conducted extensive preliminary exploration work from 2012 to 2015 which included geophysical surveys (Magnetic-Electromagnetic-Gravity) and geochemical surveys (soils) to bring the property to drill-ready targets. The surveys identified 5 first priority targets to be explored. The previous drilling operation along the 7 km long favorable horizon was conducted in 1956 and included only 10 short holes.
Murray Brook Mining Lease (# 252)
The Murray Brook Mining Lease is located in the center of the area of interest and hosts the Murray Brook Deposit. The underground sulphide mineral resource estimate of the Murray Brook Deposit comprises measured and indicated mineral resources totalling 5.28 million tonnes averaging 5.24 per cent zinc, 1.80 per cent lead, 0.46 per cent copper, 68.9 grams per tonne silver and 0.65 g/t gold. It contains 610 million pounds of zinc, 209 million pounds of lead, 54 million pounds of copper, 11.7 million ounces of silver and 111,000 ounces of gold at an $85 per-tonne net-smelter-return cut-off in the sulphide measured and indicated categories. On February 20th 2017, the NI 43-101 report was accepted and filed on SEDAR.
After reviewing the current drill hole database, Puma’s geologists have defined first priority targets to verify the extension of the deposit along strike and also at depth. An EM survey defined 2 geophysical anomalies to be tested as well. On the south-west side of the deposit, a previous hole drilled in 2012 intersected 5.26{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} cu over 9.75 meters at the outer edge of the deposit and is open to the south.
Murray Brook West (7846)
The Murray Brook West Property recently acquired by map staking contains 86 claims (1,870 Hectares). It is located west and contiguous to the Murray Brook Deposit Mining lease toward the past operating Restigouche Mine over a strike length of six (6) kilometers. It covers drill-ready targets contained within a similar geological setting as the one of the Murray Brook Deposit. Puma’s geologists are currently compiling the data to prioritize those surface targets.
Preliminary Economic Assessment (PEA)
Concurrent with the field work program, Puma is working on an updated preliminary economic assessment (PEA) on its Murray Brook Deposit. The updated PEA will assess the best means of extracting mineralization and will place a capital expenditure figure on the project. Different mining scenarios are possible at Murray Brook, as the deposit starts at surface and goes at depth to 300 meters, and the higher grade sulphide zone is located between 200-300 meters deep.
Puma’s engineer is proceeding with the review and the evaluation of different metallurgy reports previously done on the Murray Brook Deposit to define the best flowsheet to be applied at the Murray Brook Deposit in order to enhance the recovery of polymetallic sulphide mineralization but also to evaluate the potential Cu-Rich oxide zone located at the top of the deposit which should improve the economics of the entire in situ mineralization.
About Puma Exploration Inc.
Puma Exploration is a Canadian mineral exploration company with advanced precious and base metals projects in Canada. The Company’s major assets are the 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per-cent beneficial interest in the Murray Brook Property, the Turgeon Zinc-Copper Project, the Nicholas-Denys Project in New Brunswick and an equity interest in Black Widow Resources related to the Little Stull Lake Gold Project in Manitoba. Puma’s objective for the coming year is to focus its exploration efforts in New Brunswick.
You can visit us on Facebook and Twitter.
Learn more by consulting www.explorationpuma.com for further information on Puma Exploration Inc.
The contents of this press release were prepared by Marcel Robillard, P.Geo., a Qualified Person as defined in NI 43-101. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements: This press release may contain forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Puma Exploration Inc. to be materially different from actual future results and achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date the statements were made, except as required by law. Puma Exploration undertakes no obligation to publicly update or revise any forward-looking statements. These risks and uncertainties are described in the quarterly and annual reports and in the documents submitted to the securities administration.
Puma Exploration Inc.
Marcel Robillard, President
(418) 724-0901
president@explorationpuma.com
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Mining, News Home, Puma Exploration
Tetra Bio-Pharma Strengthens Management Team
Tetra Bio-Pharma Strengthens Management Team
OTTAWA, ONTARIO–(Marketwired – May 10, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.
Mr. Bechard brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.
During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.
“We are most pleased to welcome Bob to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Bechard has built great relations over his career in the pharmaceutical industry which will open new opportunities to further expand our product pipeline through partnerships as we build Tetra into a global leader in pharmaceutical cannabis.”
About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(343) 689-0714
edward@tetrabiopharma.com
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Mobi724 Global Solutions Inc. Closes the Last Portion of the Acquisition with Former Shareholders of I.Q. 7/24 Inc. on Better Terms to Focus on its Growth Strategy Plan
Mobi724 Global Solutions Inc. Closes the Last Portion of the Acquisition with Former Shareholders of I.Q. 7/24 Inc. on Better Terms to Focus on its Growth Strategy Plan
MONTREAL, QUEBEC–(Marketwired – May 11, 2017) – MOBI724 Global Solutions Inc. (“MOBI724” or the “Company”) (CSE:MOS)(CSE:MOS.CN)(CNSX:MOS)(OTCQB:MOBIF), a Fintech leader offering all in one fully integrated EMV payment, card link couponing and digital marketing, announces that it has successfully renegotiated the terms of the balance of sale of the acquisition of its wholly owned subsidiary I.Q. 7/24 Inc (“IQ”) and that it has paid the IQ former shareholders the amount of $800,000 in cash and has issued 3,492,958 common shares (the “Shares”) at a price of $0.355 for a value of $1,240,000. The total aggregate value of the renegotiated terms of the balance is $3,099,937 in Canadian dollars. After the aforesaid payment in cash and the issuance of the Shares, a final payment in the amount of $1,059,937 will be payable by September 10, 2017.
Marcel Vienneau, the CEO of the Company said, “We are very content with the outcome of the renegotiated terms as it will bring value to the Company. The renegotiated terms gives the Company the opportunity save approximately 2M dollars on the purchase Price which is a huge benefit to the Company and its shareholders. Both parties win as IQ724 gets their shares now and will benefit from the value created forward as we both focus on value creation. There are multiple synergies that will be acted upon now; there are many opportunities to grow this vertical from our global reach and mostly leverage IQ724 expertise and solutions for payment card issuers globally.” “We at iQ724 are excited and look forward to the next stage of our relationship with MOBI724 and that is leveraging our complimentary skill sets and technological advancements to generate innovative and profitable solutions for our customers,” said Daniel Tardif, President of iQ724.
About Mobi724 Global Solutions
Mobi724, a leader in the fintech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment & digital marketing solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing platform that works on any card and any mobile device. Mobi724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. Mobi724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. Mobi724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enables card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
Forward-Looking Statements
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
MOBI724 Global Solutions Inc.
Marcel Vienneau
1-514-394-5200 x 413
www.mobi724.com
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Financial Technology, Mobi724 Global Solutions, News Home, Technology